Research

Energy balance

Up to half of patients discontinue obesity medications within 1 to 2 years due to various reasons.

Practitioners should be aware of high discontinuation rates and address barriers to adherence.

StrongSupportsmedium confidence
up to half of patients discontinue treatment within 1 to 2 years due to side effects, limited access, cost, or inadequate response.
Sarah R. Barenbaum et al. · The Journal of Clinical Endocrinology & Metabolism · 2025

Why this rating

The claim is based on observed patient behavior.

Source

Approach to the Patient: Clinical Outcomes and Interim Strategies Following Discontinuation of Incretin Agonists

Sarah R. Barenbaum et al. · The Journal of Clinical Endocrinology & Metabolism · 2025

DOI 10.1210/clinem/dgaf641

case_study
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →